Discuss this article
We feel it is important that health care professionals are made aware of the available evidence supporting the use of this vaccine in order that they are able to make an informed choice about the best care for their patients, and therefore we provide additional information to supplement the review article. It is the only modern pneumococcal conjugate vaccine with impact on invasive pneumococcal disease, pneumonia and acute otitis media that has been proven in two pivotal randomized controlled efficacy trials performed in Finland and Latin America 2-4 . Thanks to its world-wide use, there is also a plethora of post-marketing and epidemiology data spanning five continents, recently reviewed by Plosker 8 , that proves its impact on the pneumococcal disease and makes it a worth-while alternative to the pneumococcal conjugate vaccine PCV13 which the health care community should be made aware of [5] [6] [7] . We have summarized the main effectiveness and impact data in Table 1 . Author contributions IV wrote the abstract and the main body of the article. BH supervised the process. Both authors critically edited the correspondence and agreed to the final content.
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I read with great interest the letter of Vojtek and Hoet. Well done and necessary. I have some remarks and suggestions:
In the abstract the term "pre-approved" is not clear to all the readers. The exact date of approval would be useful because it could inform the readers that PHiD-CV has a long and great history.
Page 2: "prequalified" is not clear (see above)
Page 2 , second column, third line. I would add "evidence based" before "informed choice" in order to stress the big amount of available rigorous data.
Page 2, 11th line: I would say "proves its impact…" beneficial It should be underlined that PHiD-CV is approved for use in children younger than 5 years of age (that could be one the reason why it was not quoted in the paper of Feldam which focuses mostly on adult/elderly patients)
In the table I would add "schedule" before "3+1" or "2+1" . In the current version one may read "minus 3 plus 1" and may misunderstand.
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